US20050209573A1 - Method and apparatus for percutaneously accessing a pressure activated implanted port - Google Patents
Method and apparatus for percutaneously accessing a pressure activated implanted port Download PDFInfo
- Publication number
- US20050209573A1 US20050209573A1 US11/130,932 US13093205A US2005209573A1 US 20050209573 A1 US20050209573 A1 US 20050209573A1 US 13093205 A US13093205 A US 13093205A US 2005209573 A1 US2005209573 A1 US 2005209573A1
- Authority
- US
- United States
- Prior art keywords
- port
- access
- implantable
- implantable port
- valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
- A61M2039/0211—Subcutaneous access sites for injecting or removing fluids with multiple chambers in a single site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/04—Tools for specific apparatus
Definitions
- the present invention relates generally to the design and use of medical devices, and more particularly to the design and use of an implantable port having a simplified design that establishes temporary access to a body lumen in the patient.
- Access to a patient's vascular system can be established by a variety of temporary and permanently implanted devices. Most simply, temporary access can be provided by the direct percutaneous introduction of a needle through the patient's skin and into a blood vessel. While such a direct approach is relatively simple and suitable for some applications, they are not suitable for hemodialysis, peritoneal dialysis, and hemofiltration. Such a direct approach is also inconvenient for other procedures, such as insulin or drug delivery procedures, which are repeated frequently over the lifetime of the patient.
- the port includes a chamber having an access region, such as a septum, where the chamber is attached to an implanted cannula which in turn is secured to a blood vessel.
- a septum In the case of veins, the cannula is typically indwelling, and in the case of arteries, the cannula may be attached by conventional surgical technique.
- Percutaneous access to a port through a septum is generally limited to small diameter, non-coring needles. Large diameter needles will core the septum, i.e. form permanent channels therethrough, which will destroy the septum after repeated uses. Unfortunately, even the use of small diameter, non-coring needles will eventually cause a septum to fail due to repeated septum penetrations.
- Implantable ports having an access aperture and internal valve mechanism for isolating the implanted cannula have also been proposed.
- One type of implantable valved port is described in a series of issued of U.S. patents which name William Ensminger as inventor.
- the Ensminger access ports have internal lumens for receiving a percutaneously introduced needle and an internal valve structure for isolating the port from an associated implanted cannula.
- the Ensminger ports have a needle-receiving aperture which is oriented at an inclined angle relative to the patient's skin.
- the Ensminger ports employ relatively entry ports having large funnel-like tapers and troughs so that needles can be introduced through many different sites in accordance with conventional procedures.
- the Ensminger patents do not describe port access using large diameter, coring needles, such as fistula needles. Moreover, as many of the specific Ensminger designs employ elastomeric valve elements, it is likely that the valve mechanisms would be damaged if the ports were accessed by a fistula needle or other large bore coring needle. Representative Ensminger patents are listed in the Description of the Background Art below.
- the improved methods and apparatus should reduce patient trauma, reduce cost, simplify apparatus design, provide for reliable access to the vasculature, minimize the risk of infection to the patient, and preferably require only minor modifications to present procedures. At least some of these objectives will be met by the invention described hereinafter.
- U.S. Pat. No. 5,562,617 and WO 95/19200 assigned to the assignee of the present application, describe implantable vascular access systems comprising an access port having an internal slit or duck bill valve for preventing back flow into the port.
- Vascular access ports having various articulating valves for isolating the port from the vascular system in the absence of external percutaneous connection to the port are described in the following U.S. Patents which name William Ensminger as an inventor: U.S. Pat. Nos.
- Implantable ports and subcutaneous catheters for connecting the ports for hemodialysis, peritoneal dialysis, and other procedures which may be useful in the present invention are described in co-pending application Ser. Nos. 08/539,105; 08/724,948; 09/009,758; 08/942,990; 08/857,386; 08/896,791; 08/856,641; and 09/003,772, the full disclosures of which are incorporated herein by reference.
- the present invention provides improved methods, apparatus, and kits for creating and establishing access to subcutaneously implanted ports for a variety of medical purposes such as drug delivery and the like.
- the present invention advantageously provides implantable ports of a simplified design and construction which open and close based on various levels of pressure differentials.
- the present invention preferably provides methods and apparatus which combine the advantages of a “buttonhole” access technique, such as low pain needle insertion and formation of a denervated tissue tract, with the advantages of subcutaneous port access, e.g. reliable performance and low failure rates, high blood and fluid flows through the port with minimum degradation of the blood or other fluid, and the ability to utilize an internal valve to provide improved isolation of the blood vessel or other accessed body lumen.
- a buttonhole access technique is described in commonly assigned, co-pending U.S. patent application Ser. No. 09/161,068 (Attorney Docket No. 17742-001420, filed on Sep. 25, 1998), the full disclosure of which is incorporated herein by reference for all purposes.
- tissue tracts created and utilized by the present invention are not the same type of tunnel which is developed over time with “button hole” fistula access technique known in the art. It is presently believed that the improved tissue tract formed by the present invention results at least partly from the ability of a valved or other self-closing port to inhibit back bleeding into the tissue tract when the needle is withdrawn. The inhibition of back bleeding substantially eliminates the need to remove blood clots from the track (which is painful for the patient) and thus reduces the risk of blood clot embolism.
- an implantable port for use in medical procedures comprises a body having a flow passage therethrough.
- the flow passage has an upstream end and a downstream end, where at least one portion of the upstream end is adapted to sealingly engage an access tube that is inserted into said upstream end.
- This passage is optionally tapered so as to facilitate the sealing engagement with the access tube.
- the taper in the passage can also advantageously accommodate needles of slightly varying diameters.
- a pressure-responsive valve element is positioned in the flow passage downstream from the upstream portion so that the access tube can be fully inserted into said upstream portion without engaging the valve element.
- the pressure-responsive valve element is preferably closed in the absence of a differential pressure above a threshold level.
- the port according to the present invention has a body comprising a housing and a housing insert.
- the housing may be made of a noncorrosive material such as stainless steel or titanium while the insert is typically made of a compliant material such as silicone.
- the housing and housing insert may made from the same homogenous material.
- the implantable port design is preferably simplified by having the pressure-responsive valve element integrally formed with the insert. In this manner, the interior structure of the port may be simplified for cost-effective manufacturing. Use of such an integrated pressure valve element is possible in the port since not all medical applications may require the bidirectional flow capability used for such extracorporal procedures as hemodialysis and the like. Although such bidirectional flow may still be possible if sufficient suction or differential pressure is present, the pressure-responsive valve of the present embodiment is particularly suited for fluid infusion such as for drug delivery.
- the threshold level of pressure required to activate the valve is preferably about 2 psi.
- a method for delivering a substance to a subcutaneous target site comprises percutaneously introducing an access tube to an implanted port having a flow passageway with an upstream end, a downstream end, and a valve element therein.
- the access tube is introduced to seat in the passage but the tube does not engage the valve element.
- the access tube and a seat interface in the passages form a seal. This minimizes needle damage to a fluid path sealing element of the port, something that plagues the performance of conventional ports.
- the substance is introduced into the flow passage through the access tube at a pressure sufficient to open the valve element to permit flow through the flow passageway to the target site.
- repeated percutaneous introductions of the access tube into the patient will create a unique tissue tract which becomes lined with scar tissue and has lessened nerve sensitivity, reducing patient trauma as the same tissue tract continues to be used for access.
- a blunt cannula may be able to pass inwardly through the established tissue tract.
- the access tube will have a diameter which is larger than that of the tissue tract which will have collapsed after the cannula was removed in the previous treatment protocol. Thus, as the blunt cannula is introduced through the established tissue tract, the tissue tract will be dilated.
- the access intervals and time periods will depend at least in part on the procedures to be performed on the patient.
- patients undergoing insulin treatments will typically have the needle or cannula introducing step repeated at intervals of up to four times a day, usually for indefinite periods.
- the needle or cannula will be introduced in a consistent direction, e.g. generally normal or perpendicular to the skin surface through which it is being introduced, with the repeated access steps eventually creating the nerve depleted tissue tract described above.
- the tissue tract may be formed vertically, thus lessening its length and further reducing bleeding and patient trauma.
- the access port is also particularly easy to locate beneath the skin, and when combined with the ability to vertically introduce the needle, targeting of the port is greatly simplified.
- the ability to accurately and simply target the port lessens the chance that the cannula will be misdirected, still further reducing patient trauma and enhancing the unique tissue tract formation which underlies the present invention.
- Kits according the present invention may comprise an implantable port together with instructions for use setting forth any of the methods described for implanting the port and creating a cannula access tract to the port.
- the port and the instructions for use will typically be packaged together, using any of the packages described hereinafter, and other kit components, such as a penetrating element, access tube, or the like, may also be provided.
- FIGS. 2-3 are cross-sectional views of another embodiment of an implantable port according to the present invention being accessed by an access tube;
- FIGS. 4A-4B show cross-sectional views of alternative embodiments of an implantable port according to the present invention.
- FIGS. 5A-5D show top and cross-sectional views of another embodiment of an implantable port according the present invention.
- FIGS. 6-7 illustrate one technique for creating and accessing a subcutaneously implanted port according to the methods of the present invention
- FIGS. 8-9 illustrate use of an access tube for creating and accessing a subcutaneously implanted port according to the methods of the present invention.
- FIG. 10 illustrates a kit according to the present invention comprising a subcutaneously implantable port, a package, and instructions for use describing how to create an access tract according to the present invention.
- the methods and apparatus of the present invention for percutaneously accessing an implantable port is useful in a variety of long-term medical procedures such as insulin drug delivery and the like.
- the methods of the present invention may be performed with implantable ports having one, two, three, or more, discrete access ports which may be vertically or otherwise repeatedly aligned with the access tract to be percutaneously formed through overlying tissue.
- Such access tracts will be useful for repeated access to the aperture, where the aperture defines a specific target site through the overlying tissue.
- the use of valved ports provide for positive shutoff and isolation of the attached body lumen, and in particular provide for complete cessation of back bleeding when an access tube is removed from ports attached to blood vessels.
- An implantable port of the present design advantageously allows for frequent cannulation without a septum to wear out. Additionally, the use of an implantable port with the buttonhole tissue tract facilitates frequent drug delivery injections and thus promotes better compliance to drug insulin therapy in a diabetic patient.
- implantable port 10 having a body 11 in accordance with the principles of the present invention will be described.
- implantable port 10 comprises the body 11 having a housing 12 optionally made of a non-corrosive material such as stainless steel or titanium and a housing insert 14 optionally made of a compliant material such as silicone or other elastomeric material.
- the body 11 defines a flow passage 20 having an upstream end 22 and a downstream end 24 .
- at least some portion of the upstream end 22 is adapted to sealingly engage an access tube N inserted into the upstream end of the passage 20 .
- the passage 20 preferably has an opening or aperture 25 located on an upper surface of the body 11 .
- such a seal may be formed in the upstream end 22 by having the end 22 formed as a tapered passage so that the side walls of an access tube such as a needle or cannula radially engages the passage.
- the upstream end 22 of the passage 20 may be tapered to fit with a variety of different sized needles.
- the passage 20 may use other sealing devices in end 22 such as an elastomeric ring or tube to form a radial seal with the needle N.
- the needle N may also comprise a non-standard needle having a beveled distal tip to facilitate the radial engagement with the passage 20 or an elastomeric O-ring. A conventional needle may damage the O-ring during insertion.
- a catheter 30 with a lumen 32 or similar elongate tubing is connected to the passage 20 near the downstream end 24 to deliver fluids or materials injected by the needle N to a target site within the body.
- FIGS. 2 and 3 also illustrate an outlet or nipple 34 which may be used to releasably couple the implantable port 10 with catheter 30 .
- the catheter 30 is substantially similar to standard catheters used with insulin pumps known in the art.
- a pressure-responsive valve element 40 is positioned in the flow passage 20 downstream from the upstream end or portion 22 of the passage.
- the pressure-responsive valve element 40 is a pressure-actuated slit valve that is optionally integrally formed in the housing insert 14 to define an integrally formed component.
- the pressure-responsive valve element 40 may be a separate element such as an articulating leaflet valve, preferably allowing flow in only one direction. Sufficient pressure differential, however, may still allow bidirectional flow if slit valves are used.
- the pressure-responsive valve element 40 is positioned in the flow passage 20 such that the access tube or needle N can be fully inserted into the upstream portion 22 without engaging the valve element.
- the valve element 40 typically remains in a closed state in the absence of a differential pressure above a threshold level.
- a threshold level For example, for syringe drug delivery such as insulin injections, the valve element will open when pressure exceeds a threshold level of about 0.25 to 25.0 psi, preferably about 1-5 psi.
- pressure responsive valve element is not necessarily integrally formed with the insert 14 of the implantable port 10 .
- the body of implantable port 41 is made of a homogenous material and the valve element such as articulating valve 42 is attached to this homogenous material.
- a valve such as the articulating valve 42 may be incorporated into part of the nipple element 34 which is screwed or threaded into the port 41 .
- the implantable port 10 may have hardened material such as stainless steel selectively located along areas such as the upper surface of the port body or the upstream end of the passage 20 which may be frequently engaged by the needle N.
- the portion of the passage 20 which engages the needle N preferably has a radial stiffness greater than the radial stiffness of the needle.
- the present invention has particular application with syringes or other pressurized delivery systems for the injection of materials into the body.
- the present application finds particular use in facilitating the daily injections of insulin required by some patients with diabetes.
- the present invention may also find application in other drug delivery roles.
- a pressure source such as syringe S is used to deliver fluid into the implantable port 10 .
- the injection pressure from the syringe S is preferably sufficient to open the slit valve 40 , thus allowing infusion of drugs or materials into the catheter or conduit 30 .
- the threshold pressure is preferably selected so that a manually operated injection device such as a syringe S can create sufficient pressure to open and flow fluid through the normally closed valve.
- the threshold level of pressure required to open the slit valve 40 or other pressure sensitive valve element is typically between 0.25 and 25.0 psi, and preferably between about 1.0 and 5.0 psi. A small syringe used for insulin delivery can easily generate pressures of excess of 100 psi.
- FIG. 4A shows a port 48 where the upper end 22 of passage 20 may be oriented at other angles as shown by the orientation of flow passage 20 . This may allow for other angles of injection as desired.
- an opening 50 of a smaller diameter which prevent further needle penetration, some embodiments of the port may have upstream end 22 axially aligned with the longitudinal axis of the downstream end 24 . The smaller diameter or use of some other stop prevents contact or accidental penetration of the pressure-responsive valve element 40 by the needle N.
- the opening 50 may be positioned in a variety of orientations, such as on the side wall of upstream portion 22 , depending on the configuration of the passage 20 .
- the port 48 and other port embodiments may have the catheter 30 coupled to the port through a cannula 52 with a nipple 54 , instead of integrated with the port as shown in FIG. 1 .
- FIG. 4B shows a further embodiment of the port of the present invention where the pressure-activated valve 60 is located at a distal tip of the catheter 62 .
- the fluid flows in a passage that extends from the port through the catheter.
- the port 64 used in this embodiment typically does not have a valve located within the port.
- the valve may be located at the distal tip of the catheter or anywhere along the catheter 62 .
- a valve 66 shown in phantom may be located at a midpoint of the catheter 62 .
- this implantable port device 68 employs a single fluid chamber 70 .
- the base and sides of the fluid chamber 70 are formed by the walls of the body 72 of the device 68 .
- the body 72 is shaped so as to define the base and sides of the fluid chamber 70 , and is further shaped to accept a cover 74 .
- the cover 74 serves to hold a replaceable diaphragm 76 which forms the top of the fluid chamber 70 .
- the cover 74 and the body 72 are shaped to allow for easy removal of the cover 74 if replacement of the diaphragm 76 is needed.
- An outlet 78 extends from the fluid chamber 70 and serves to connect the chamber 70 with a cannula 80 .
- the cannula 80 connects the fluid chamber 70 to the target vascular structure, which may be an artery or vein.
- the implantable port 68 employs a flap valve device 84 comprised of two sheets of compliant material 86 layered upon each other and bonded to each other along their lateral edges.
- This configuration allows for creation of an opening 88 between the two sheets of compliant material 86 , as shown in FIG. 5C , a cross section taken along line 5 C- 5 C. Opening 88 within the cannula 80 is created when positive pressure is achieved within the fluid chamber 70 or when the flap valve 84 is traversed by a percutaneous needle through the diaphragm 76 .
- Obliteration of the opening 88 and thus closure of the flap valve 84 is achieved by reversal of the pressure gradient attended by removal of the percutaneous needle and exertion of extravascular pressure upon extralumenal portions 92 within the cannula 80 , as shown in FIG. 5D , a cross section along line 5 D- 5 D.
- the fluid chamber 70 and connecting cannula 80 may be filled with anticoagulant material or anti-microbial cleaning fluids when the port 68 is not in use.
- the pressure flap valve 84 prevents reflux of blood and subsequent washout of anticoagulant material or anti-microbial cleaning fluids during periods when the device 68 is not is use.
- the body 72 of the implantable port 68 may be manufactured of surgical metal. Other materials of manufacture are acceptable provided they are compatible with the person or animal into which the port 68 is implanted, and do not adversely affect the tissue to which the port 68 is attached. Additionally, the body 72 should be manufactured of a material of sufficient hardness to resist being damaged or gouged by needles or other tissue penetrating elements which will be inserted through the diaphragm 76 into the fluid chamber 70 . The diaphragm 76 should be manufactured of a material tolerant of multiple penetrations with needles without sacrificing the integrity of the diaphragm 76 .
- the cannula 80 may be manufactured of PTFE, or other suitable material which is compatible with the surrounding tissues and is resistant to collapse.
- the flap valve 84 is preferably manufactured of the same material as the cannula 80 , but may be manufactured of any suitable material which has sufficient flexibility to allow passage of fluid through the lumen of the cannula 80 when a pressure differential exists between the target vascular structure and the fluid chamber 70 , but will also retard flow or diffuison through the lumen of the cannula 80 when no significant pressure differential exists.
- a port 10 is implanted by creating a tissue pocket PT by making an incision in the skin S and forming the pocket laterally from the incision.
- the port 10 may then be placed in the pocket PT and connected to a cannula in any manner.
- a presently preferred manner of connecting the port 10 to the cannula 30 is described in co-pending application Ser. No. 09/238,523 (Attorney Docket No. 17742-002800, filed on Jan. 27, 1999, entitled Access System and Methods having Reversible Cannulas), the full disclosure of which is incorporated herein by reference.
- tissue penetrating element which may be a needle, rod, stylet, tube, or virtually any other penetrating element, may then be introduced through the intact region of skin IR, as shown in FIG. 8 .
- Other suitable tissue penetrating elements are described in co-pending U.S. patent application Ser. No. 09/161,068 (Attorney Docket No. 17742-001420, filed on Sep. 25, 1998), the full disclosure of which is incorporated herein by reference for all purposes.
- the tissue tract of the present invention may be established at any time after a port has been subcutaneously implanted. In many instances, it will be desirable to begin creating the tissue tract at the time the port is initially implanted.
- a syringe S having a syringe needle N is used as the penetrating element, but it will be appreciated that this is not necessary for initial tissue tract formation.
- Other access tubes may be used during the initial periods.
- the penetrating element may be left in place transcutaneously through the skin for a time sufficient to at least begin forming the tissue tract, usually for at least one week, preferably for at least two weeks. After that initial time, the tissue penetrating element may be removed and the resulting tissue tract accessed using access tubes according to the method of the present invention described below.
- a particular advantage of this method for creating the access tract is that the tract will be formed simultaneously with healing of the surgical introduction of the port and associated subcutaneous cannula.
- a further advantage, when an access tube is used as the penetrating element, is that fluids may be introduced and removed from the port during the healing period.
- the port 10 will have an aperture or opening 25 which is preferably oriented to receive a vertically aligned needle. That is, the access needle N will preferably be percutaneously introduced through the skin surface in a direction which is normal to or perpendicular to the plane of the skin at the point where the needle is being introduced. While vertical access is preferred and may be accomplished using the exemplary ports of the present invention, percutaneous access according to the present invention may also be achieved used non-vertical access direction, i.e. where access is accomplished by penetrating a needle or other device at a relatively low angle relative to the skin, often between 15° and 45° relative to the skin surface.
- the port 10 of the present invention does not have a needle guide channel, trough, or extended funnel at the opening of passage 20 since such a funnel or trough may allow the user to penetrate the access tube through different access tracts.
- the access needle N After entering the port 10 , the access needle N will preferably engage with a tapered portion of the upstream end 22 of passage 20 to form a seal.
- the needle N does not engage the valve element 40 , which in the preferred embodiment, is located in a portion of the passage 20 oriented at a 90° to the upstream end 22 .
- the access tube may inserted using a method as further described in commonly assigned, copending application Ser. No. 09/238,461 (Attorney Docket No. 17742-000620 entitled Devices and Methods for Accessing an Implanted Port, filed Jan. 29, 1999), the full disclosure of which is incorporated herein by reference.
- the access tube or needle N is inserted to establish a flow path with a lumen in cannula 30 , where the cannula may be connected to a blood vessel or other body lumen or cavity, as described in detail in co-pending application Ser. No. 08/856,641, filed on May 15, 1997, now U.S. Pat. No. 5,931,829.
- the access needle N may be aligned over the aperture 25 by manually feeling the top of the port 10 .
- the port 10 is generally symmetric with the aperture 25 positioned in the center of the port. The user can feel the periphery of the port P and visually determine its center.
- the access needle N is then vertically penetrated through the skin and into the aperture, as shown in FIG. 8 .
- the thickness of tissue T overlying the aperture is generally from 3 mm to 15 mm, as described above.
- a port 10 may be packaged together with instructions for use (IFU) in a kit.
- a conventional package 100 which may be in the form of a pouch, tray, box, tube, or the like, may be used to contain both the port and the instructions for use.
- Additional kit components such as a penetrating element, access tube, a catheter, or the like, may also be included in the kit.
- all kit components may be sterilized within the package, and the instructions for use may be set forth on a separate sheet of paper and/or on the packaging itself.
- the instructions may set forth any of the aspects of the method of the present invention for implanting the port or subsequently accessing the port using an access tube as described above.
Abstract
Methods and apparatus for percutaneously accessing an implanted port using an access tube which is periodically introduced to the implanted port. The apparatus is preferably an implantable port having a pressure-responsive valve element. It has been found that repeated passage of the access tube through the same tissue tract to the implantable port reduces patient trauma, with minimized bleeding and reduction in sensitivity. The tract may be initially formed by percutaneously placing a penetrating element through intact skin to the port and leaving the element in place for a time sufficient to created the tract.
Description
- This application is a Continuation of U.S. patent application Ser. No. 09/595,167, filed on Jun. 15, 2000, which was a Continuation-In-Part of U.S. patent application Ser. No. 09/239,411, filed Jan. 28, 1999, now abandoned, and also was a Continuation-In-Part of U.S. patent application Ser. No. 09/561,374, filed Apr. 28, 2000, now abandoned, which was a Continuation of application Ser. No. 09/017,045, filed Feb. 2, 1998, now U.S. Pat. No. 6,056,717, which was a Continuation of application Ser. No. 08/745,903, filed Nov. 7, 1996, now U.S. Pat. No. 5,755,780, which was a Continuation of application Ser. No. 08/480,117, filed Jun. 7, 1995, now abandoned, which was a Division of application Ser. No. 08/183,151, filed Jan. 18, 1994, now U.S. Pat. No. 5,562,617, and which also was a Continuation of application Ser. No. 08/634,634, filed Apr. 18, 1996, now U.S. Pat. No. 5,713,859, which was a Continuation of application Ser. No. 08/183,151, filed Jan. 18, 1994, now U.S. Pat. No. 5,562,617, all of which are incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates generally to the design and use of medical devices, and more particularly to the design and use of an implantable port having a simplified design that establishes temporary access to a body lumen in the patient.
- Access to a patient's vascular system can be established by a variety of temporary and permanently implanted devices. Most simply, temporary access can be provided by the direct percutaneous introduction of a needle through the patient's skin and into a blood vessel. While such a direct approach is relatively simple and suitable for some applications, they are not suitable for hemodialysis, peritoneal dialysis, and hemofiltration. Such a direct approach is also inconvenient for other procedures, such as insulin or drug delivery procedures, which are repeated frequently over the lifetime of the patient.
- A variety of implantable ports have been proposed over the years to provide long-term vascular access for hemodialysis, hemofiltration, and other medical treatments. Typically, the port includes a chamber having an access region, such as a septum, where the chamber is attached to an implanted cannula which in turn is secured to a blood vessel. In the case of veins, the cannula is typically indwelling, and in the case of arteries, the cannula may be attached by conventional surgical technique. Percutaneous access to a port through a septum is generally limited to small diameter, non-coring needles. Large diameter needles will core the septum, i.e. form permanent channels therethrough, which will destroy the septum after repeated uses. Unfortunately, even the use of small diameter, non-coring needles will eventually cause a septum to fail due to repeated septum penetrations.
- Implantable ports having an access aperture and internal valve mechanism for isolating the implanted cannula have also been proposed. One type of implantable valved port is described in a series of issued of U.S. patents which name William Ensminger as inventor. The Ensminger access ports have internal lumens for receiving a percutaneously introduced needle and an internal valve structure for isolating the port from an associated implanted cannula. Generally, the Ensminger ports have a needle-receiving aperture which is oriented at an inclined angle relative to the patient's skin. The Ensminger ports employ relatively entry ports having large funnel-like tapers and troughs so that needles can be introduced through many different sites in accordance with conventional procedures. The Ensminger patents do not describe port access using large diameter, coring needles, such as fistula needles. Moreover, as many of the specific Ensminger designs employ elastomeric valve elements, it is likely that the valve mechanisms would be damaged if the ports were accessed by a fistula needle or other large bore coring needle. Representative Ensminger patents are listed in the Description of the Background Art below.
- Although promising, these known valve-type implantable ports are not without limitations. For one thing, these known ports are expensive and that limits their applicability to a broader range of medical treatments. Such implantable ports typically have an interior structure having many moving parts and elements as evidenced by the devices of the Ensminger patents. The complicated interior of these known ports increases the cost per part of each implantable port. Although not true in all circumstances, the additional parts may also increase the probability that one of these parts may fail. The plurality of parts also increases the level of skill required to assemble each implantable port. Additionally, some of these known implantable ports still have valves which contact the needle and will wear out due to needle damage incurred during repeated use. Furthermore, to the extent that implantable ports have been used, it has generally been recommended that the access site be moved relative to the port in order to change the location of the tissue tract between successive access procedures.
- For these reasons, it would be desirable to provide improved methods and apparatus for percutaneously accessing a patient's vasculature. The improved methods and apparatus should reduce patient trauma, reduce cost, simplify apparatus design, provide for reliable access to the vasculature, minimize the risk of infection to the patient, and preferably require only minor modifications to present procedures. At least some of these objectives will be met by the invention described hereinafter.
- 2. Description of the Background Art
- U.S. Pat. No. 5,562,617 and WO 95/19200, assigned to the assignee of the present application, describe implantable vascular access systems comprising an access port having an internal slit or duck bill valve for preventing back flow into the port. Vascular access ports having various articulating valves for isolating the port from the vascular system in the absence of external percutaneous connection to the port are described in the following U.S. Patents which name William Ensminger as an inventor: U.S. Pat. Nos. 5,527,278; 5,527,277; 5,520,643; 5,503,630; 5,476,451; 5,417,656; 5,350,360; 5,281,199; 5,263,930; 5,226,879; 5,180,365; 5,057,084; and 5,053,013. Other patents and published applications which show implantable ports having valve structures opened by insertion of a needle include U.S. Pat. Nos. 5,741,228; 5,702,363; 4,569,675; 4,534,759; 4,181,132; WO 97/47338; and WO 96/31246. Devices for hemodialysis or devices having one piece valves are described in U.S. Pat. Nos. 4,892,518; 5,098,405; and 5,125,897. Implantable ports and subcutaneous catheters for connecting the ports for hemodialysis, peritoneal dialysis, and other procedures which may be useful in the present invention are described in co-pending application Ser. Nos. 08/539,105; 08/724,948; 09/009,758; 08/942,990; 08/857,386; 08/896,791; 08/856,641; and 09/003,772, the full disclosures of which are incorporated herein by reference.
- The present invention provides improved methods, apparatus, and kits for creating and establishing access to subcutaneously implanted ports for a variety of medical purposes such as drug delivery and the like. The present invention advantageously provides implantable ports of a simplified design and construction which open and close based on various levels of pressure differentials.
- In particular, the present invention preferably provides methods and apparatus which combine the advantages of a “buttonhole” access technique, such as low pain needle insertion and formation of a denervated tissue tract, with the advantages of subcutaneous port access, e.g. reliable performance and low failure rates, high blood and fluid flows through the port with minimum degradation of the blood or other fluid, and the ability to utilize an internal valve to provide improved isolation of the blood vessel or other accessed body lumen. Such a buttonhole access technique is described in commonly assigned, co-pending U.S. patent application Ser. No. 09/161,068 (Attorney Docket No. 17742-001420, filed on Sep. 25, 1998), the full disclosure of which is incorporated herein by reference for all purposes. It has been observed that the tissue tracts created and utilized by the present invention are not the same type of tunnel which is developed over time with “button hole” fistula access technique known in the art. It is presently believed that the improved tissue tract formed by the present invention results at least partly from the ability of a valved or other self-closing port to inhibit back bleeding into the tissue tract when the needle is withdrawn. The inhibition of back bleeding substantially eliminates the need to remove blood clots from the track (which is painful for the patient) and thus reduces the risk of blood clot embolism.
- In a first aspect of the present invention, an implantable port for use in medical procedures comprises a body having a flow passage therethrough. The flow passage has an upstream end and a downstream end, where at least one portion of the upstream end is adapted to sealingly engage an access tube that is inserted into said upstream end. This passage is optionally tapered so as to facilitate the sealing engagement with the access tube. The taper in the passage can also advantageously accommodate needles of slightly varying diameters. A pressure-responsive valve element is positioned in the flow passage downstream from the upstream portion so that the access tube can be fully inserted into said upstream portion without engaging the valve element. The pressure-responsive valve element is preferably closed in the absence of a differential pressure above a threshold level.
- In one embodiment, the port according to the present invention has a body comprising a housing and a housing insert. The housing may be made of a noncorrosive material such as stainless steel or titanium while the insert is typically made of a compliant material such as silicone. In other embodiments, the housing and housing insert may made from the same homogenous material. The implantable port design is preferably simplified by having the pressure-responsive valve element integrally formed with the insert. In this manner, the interior structure of the port may be simplified for cost-effective manufacturing. Use of such an integrated pressure valve element is possible in the port since not all medical applications may require the bidirectional flow capability used for such extracorporal procedures as hemodialysis and the like. Although such bidirectional flow may still be possible if sufficient suction or differential pressure is present, the pressure-responsive valve of the present embodiment is particularly suited for fluid infusion such as for drug delivery. The threshold level of pressure required to activate the valve is preferably about 2 psi.
- The port according to the present invention generally has an opening on the upstream end of the passageway with dimensions which correspond to those of the access tube, e.g. they will have similar diameters, or with an opening comprising a funnel having dimensions substantially larger than the access tube diameter. Usually, however, provision of such a funnel at the opening for directing the access tube into the opening is undesirable since it allows the user to penetrate the access tube through different access tracts. To minimize wear and needle damage after the penetration into the port, the downstream end of the passageway in the port body is preferably disposed at a 90° angle relative to the upstream end which receives the access tube. Of course, the passageway may be disposed at other angles in the passageway. The bend in the passageway prevents the access tube from contacting and damage the pressure-responsive valve element.
- According to a second aspect of the present invention, a method for delivering a substance to a subcutaneous target site comprises percutaneously introducing an access tube to an implanted port having a flow passageway with an upstream end, a downstream end, and a valve element therein. The access tube is introduced to seat in the passage but the tube does not engage the valve element. The access tube and a seat interface in the passages form a seal. This minimizes needle damage to a fluid path sealing element of the port, something that plagues the performance of conventional ports.
- The substance is introduced into the flow passage through the access tube at a pressure sufficient to open the valve element to permit flow through the flow passageway to the target site. Over time, repeated percutaneous introductions of the access tube into the patient will create a unique tissue tract which becomes lined with scar tissue and has lessened nerve sensitivity, reducing patient trauma as the same tissue tract continues to be used for access. In some cases, after the access tract is established, it will not be necessary to provide a sharpened element in order to assist in percutaneous introduction. That is, a blunt cannula may be able to pass inwardly through the established tissue tract. Usually, the access tube will have a diameter which is larger than that of the tissue tract which will have collapsed after the cannula was removed in the previous treatment protocol. Thus, as the blunt cannula is introduced through the established tissue tract, the tissue tract will be dilated.
- Usually, the access intervals and time periods will depend at least in part on the procedures to be performed on the patient. For example, patients undergoing insulin treatments will typically have the needle or cannula introducing step repeated at intervals of up to four times a day, usually for indefinite periods. Usually, although not necessarily, the needle or cannula will be introduced in a consistent direction, e.g. generally normal or perpendicular to the skin surface through which it is being introduced, with the repeated access steps eventually creating the nerve depleted tissue tract described above. By introducing the needle or cannula normal to the skin surface, the tissue tract may be formed vertically, thus lessening its length and further reducing bleeding and patient trauma. The access port is also particularly easy to locate beneath the skin, and when combined with the ability to vertically introduce the needle, targeting of the port is greatly simplified. The ability to accurately and simply target the port lessens the chance that the cannula will be misdirected, still further reducing patient trauma and enhancing the unique tissue tract formation which underlies the present invention.
- Kits according the present invention may comprise an implantable port together with instructions for use setting forth any of the methods described for implanting the port and creating a cannula access tract to the port. The port and the instructions for use will typically be packaged together, using any of the packages described hereinafter, and other kit components, such as a penetrating element, access tube, or the like, may also be provided.
- A further understanding of the nature and advantages of the invention will become apparent by reference to the remaining portions of the specification and drawings.
-
FIG. 1 is a cross-sectional view of a first embodiment of an implantable port according to the present invention; -
FIGS. 2-3 are cross-sectional views of another embodiment of an implantable port according to the present invention being accessed by an access tube; -
FIGS. 4A-4B show cross-sectional views of alternative embodiments of an implantable port according to the present invention; -
FIGS. 5A-5D show top and cross-sectional views of another embodiment of an implantable port according the present invention; -
FIGS. 6-7 illustrate one technique for creating and accessing a subcutaneously implanted port according to the methods of the present invention; -
FIGS. 8-9 illustrate use of an access tube for creating and accessing a subcutaneously implanted port according to the methods of the present invention; and -
FIG. 10 illustrates a kit according to the present invention comprising a subcutaneously implantable port, a package, and instructions for use describing how to create an access tract according to the present invention. - The methods and apparatus of the present invention for percutaneously accessing an implantable port is useful in a variety of long-term medical procedures such as insulin drug delivery and the like. The methods of the present invention may be performed with implantable ports having one, two, three, or more, discrete access ports which may be vertically or otherwise repeatedly aligned with the access tract to be percutaneously formed through overlying tissue. Such access tracts will be useful for repeated access to the aperture, where the aperture defines a specific target site through the overlying tissue. The use of valved ports provide for positive shutoff and isolation of the attached body lumen, and in particular provide for complete cessation of back bleeding when an access tube is removed from ports attached to blood vessels. An implantable port of the present design advantageously allows for frequent cannulation without a septum to wear out. Additionally, the use of an implantable port with the buttonhole tissue tract facilitates frequent drug delivery injections and thus promotes better compliance to drug insulin therapy in a diabetic patient.
- The preferred implantable ports will have at least one opening or aperture which removably receives the access tube, optionally in a vertical orientation in order to minimize distance of the tissue tract. The implantable port will preferably be capable of immobilizing the access needle while fluid is being transferred through the port. Typically, the port will be implanted beneath the skin by a distance in the range from about 3 mm to 20 mm, usually from 5 mm to 15 mm. In preferred embodiments, the access needle N comprises or is coupled to a pressure source that can be used to open a pressure-responsive valve. Such a valve is generally responsive to pressure differentials created by a pressure source such as a syringe. In some embodiments, however, the valve may be a bidirectional if a suction source or sufficient pressure differential is present to activate the valve for injection and extraction.
- Referring now to
FIG. 1 , animplantable port 10 having abody 11 in accordance with the principles of the present invention will be described. In the embodiment shown inFIG. 1 ,implantable port 10 comprises thebody 11 having ahousing 12 optionally made of a non-corrosive material such as stainless steel or titanium and ahousing insert 14 optionally made of a compliant material such as silicone or other elastomeric material. Thebody 11 defines aflow passage 20 having anupstream end 22 and adownstream end 24. Preferably, at least some portion of theupstream end 22 is adapted to sealingly engage an access tube N inserted into the upstream end of thepassage 20. Thepassage 20 preferably has an opening oraperture 25 located on an upper surface of thebody 11. In one embodiment, such a seal may be formed in theupstream end 22 by having theend 22 formed as a tapered passage so that the side walls of an access tube such as a needle or cannula radially engages the passage. Theupstream end 22 of thepassage 20 may be tapered to fit with a variety of different sized needles. Optionally, thepassage 20 may use other sealing devices inend 22 such as an elastomeric ring or tube to form a radial seal with the needle N. The needle N may also comprise a non-standard needle having a beveled distal tip to facilitate the radial engagement with thepassage 20 or an elastomeric O-ring. A conventional needle may damage the O-ring during insertion. - As shown in
FIG. 1 , acatheter 30 with alumen 32 or similar elongate tubing is connected to thepassage 20 near thedownstream end 24 to deliver fluids or materials injected by the needle N to a target site within the body.FIGS. 2 and 3 also illustrate an outlet ornipple 34 which may be used to releasably couple theimplantable port 10 withcatheter 30. For insulin drug delivery, thecatheter 30 is substantially similar to standard catheters used with insulin pumps known in the art. - Referring now to
FIGS. 1-3 , a pressure-responsive valve element 40 is positioned in theflow passage 20 downstream from the upstream end orportion 22 of the passage. In the embodiment ofFIG. 1 , the pressure-responsive valve element 40 is a pressure-actuated slit valve that is optionally integrally formed in thehousing insert 14 to define an integrally formed component. In other embodiments as shown inFIGS. 2-3 , the pressure-responsive valve element 40 may be a separate element such as an articulating leaflet valve, preferably allowing flow in only one direction. Sufficient pressure differential, however, may still allow bidirectional flow if slit valves are used. Preferably, the pressure-responsive valve element 40 is positioned in theflow passage 20 such that the access tube or needle N can be fully inserted into theupstream portion 22 without engaging the valve element. Thevalve element 40 typically remains in a closed state in the absence of a differential pressure above a threshold level. For example, for syringe drug delivery such as insulin injections, the valve element will open when pressure exceeds a threshold level of about 0.25 to 25.0 psi, preferably about 1-5 psi. - As shown in the embodiments of
FIGS. 2-3 , pressure responsive valve element is not necessarily integrally formed with theinsert 14 of theimplantable port 10. In some embodiments, the body ofimplantable port 41 is made of a homogenous material and the valve element such as articulatingvalve 42 is attached to this homogenous material. Additionally, as seen inFIG. 2 , a valve such as the articulatingvalve 42 may be incorporated into part of thenipple element 34 which is screwed or threaded into theport 41. In still other embodiments, theimplantable port 10 may have hardened material such as stainless steel selectively located along areas such as the upper surface of the port body or the upstream end of thepassage 20 which may be frequently engaged by the needle N. The portion of thepassage 20 which engages the needle N preferably has a radial stiffness greater than the radial stiffness of the needle. - Although not restricted in this manner, the present invention has particular application with syringes or other pressurized delivery systems for the injection of materials into the body. For example, the present application finds particular use in facilitating the daily injections of insulin required by some patients with diabetes. The present invention may also find application in other drug delivery roles. As shown in
FIG. 1 , a pressure source such as syringe S is used to deliver fluid into theimplantable port 10. The injection pressure from the syringe S is preferably sufficient to open theslit valve 40, thus allowing infusion of drugs or materials into the catheter orconduit 30. It should be understood that the threshold pressure is preferably selected so that a manually operated injection device such as a syringe S can create sufficient pressure to open and flow fluid through the normally closed valve. The threshold level of pressure required to open theslit valve 40 or other pressure sensitive valve element is typically between 0.25 and 25.0 psi, and preferably between about 1.0 and 5.0 psi. A small syringe used for insulin delivery can easily generate pressures of excess of 100 psi. - Referring now to
FIGS. 4A-4B andFIGS. 5A-5D , other embodiments of the access port will be described in further detail. Although the downstream end of the flow passage is preferably disposed at a 90° angle (FIG. 1 ) relative to theupstream end 22,FIG. 4A shows a port 48 where theupper end 22 ofpassage 20 may be oriented at other angles as shown by the orientation offlow passage 20. This may allow for other angles of injection as desired. By using anopening 50 of a smaller diameter which prevent further needle penetration, some embodiments of the port may haveupstream end 22 axially aligned with the longitudinal axis of thedownstream end 24. The smaller diameter or use of some other stop prevents contact or accidental penetration of the pressure-responsive valve element 40 by the needle N. As shown inFIG. 1 , however, theopening 50 may be positioned in a variety of orientations, such as on the side wall ofupstream portion 22, depending on the configuration of thepassage 20. Additionally, the port 48 and other port embodiments may have thecatheter 30 coupled to the port through acannula 52 with anipple 54, instead of integrated with the port as shown inFIG. 1 . -
FIG. 4B shows a further embodiment of the port of the present invention where the pressure-activatedvalve 60 is located at a distal tip of thecatheter 62. The fluid flows in a passage that extends from the port through the catheter. Theport 64 used in this embodiment typically does not have a valve located within the port. The valve may be located at the distal tip of the catheter or anywhere along thecatheter 62. For example, a valve 66 (shown in phantom) may be located at a midpoint of thecatheter 62. - Referring to
FIGS. 5A-5D , there is depicted another embodiment of the implantable port of the present invention. As shown inFIG. 5A , thisimplantable port device 68 employs asingle fluid chamber 70. The base and sides of thefluid chamber 70 are formed by the walls of thebody 72 of thedevice 68. As is best seen inFIGS. 5B-5D , thebody 72 is shaped so as to define the base and sides of thefluid chamber 70, and is further shaped to accept acover 74. Thecover 74 serves to hold areplaceable diaphragm 76 which forms the top of thefluid chamber 70. Thecover 74 and thebody 72 are shaped to allow for easy removal of thecover 74 if replacement of thediaphragm 76 is needed. Anoutlet 78 extends from thefluid chamber 70 and serves to connect thechamber 70 with acannula 80. Thecannula 80 connects thefluid chamber 70 to the target vascular structure, which may be an artery or vein. - As seen in
FIG. 5B , a cross section taken alongline 5B-5B, theimplantable port 68 employs aflap valve device 84 comprised of two sheets ofcompliant material 86 layered upon each other and bonded to each other along their lateral edges. This configuration allows for creation of anopening 88 between the two sheets ofcompliant material 86, as shown inFIG. 5C , a cross section taken alongline 5C-5C.Opening 88 within thecannula 80 is created when positive pressure is achieved within thefluid chamber 70 or when theflap valve 84 is traversed by a percutaneous needle through thediaphragm 76. Obliteration of theopening 88 and thus closure of theflap valve 84 is achieved by reversal of the pressure gradient attended by removal of the percutaneous needle and exertion of extravascular pressure uponextralumenal portions 92 within thecannula 80, as shown inFIG. 5D , a cross section alongline 5D-5D. Additionally, thefluid chamber 70 and connectingcannula 80 may be filled with anticoagulant material or anti-microbial cleaning fluids when theport 68 is not in use. Thus, thepressure flap valve 84 prevents reflux of blood and subsequent washout of anticoagulant material or anti-microbial cleaning fluids during periods when thedevice 68 is not is use. - The
body 72 of theimplantable port 68 may be manufactured of surgical metal. Other materials of manufacture are acceptable provided they are compatible with the person or animal into which theport 68 is implanted, and do not adversely affect the tissue to which theport 68 is attached. Additionally, thebody 72 should be manufactured of a material of sufficient hardness to resist being damaged or gouged by needles or other tissue penetrating elements which will be inserted through thediaphragm 76 into thefluid chamber 70. Thediaphragm 76 should be manufactured of a material tolerant of multiple penetrations with needles without sacrificing the integrity of thediaphragm 76. Thecannula 80 may be manufactured of PTFE, or other suitable material which is compatible with the surrounding tissues and is resistant to collapse. Theflap valve 84 is preferably manufactured of the same material as thecannula 80, but may be manufactured of any suitable material which has sufficient flexibility to allow passage of fluid through the lumen of thecannula 80 when a pressure differential exists between the target vascular structure and thefluid chamber 70, but will also retard flow or diffuison through the lumen of thecannula 80 when no significant pressure differential exists. - Referring now to
FIGS. 6-7 , a method for implanting theport 10 within the body of the patient will now be described. Aport 10 is implanted by creating a tissue pocket PT by making an incision in the skin S and forming the pocket laterally from the incision. Theport 10 may then be placed in the pocket PT and connected to a cannula in any manner. A presently preferred manner of connecting theport 10 to thecannula 30 is described in co-pending application Ser. No. 09/238,523 (Attorney Docket No. 17742-002800, filed on Jan. 27, 1999, entitled Access System and Methods having Reversible Cannulas), the full disclosure of which is incorporated herein by reference. After the tissue pocket PT is closed, as shown inFIG. 7 , an intact region of skin IR will overlay the accesstube target aperture 25. A tissue penetrating element, which may be a needle, rod, stylet, tube, or virtually any other penetrating element, may then be introduced through the intact region of skin IR, as shown inFIG. 8 . Other suitable tissue penetrating elements are described in co-pending U.S. patent application Ser. No. 09/161,068 (Attorney Docket No. 17742-001420, filed on Sep. 25, 1998), the full disclosure of which is incorporated herein by reference for all purposes. The tissue tract of the present invention may be established at any time after a port has been subcutaneously implanted. In many instances, it will be desirable to begin creating the tissue tract at the time the port is initially implanted. - In
FIG. 8 , a syringe S having a syringe needle N is used as the penetrating element, but it will be appreciated that this is not necessary for initial tissue tract formation. Other access tubes may be used during the initial periods. To help form the tissue tract, the penetrating element may be left in place transcutaneously through the skin for a time sufficient to at least begin forming the tissue tract, usually for at least one week, preferably for at least two weeks. After that initial time, the tissue penetrating element may be removed and the resulting tissue tract accessed using access tubes according to the method of the present invention described below. Continued accessing of theport 10 through the preformed tissue tract will continue to cause scarring and denervation of the tissue tract, further establishing and defining the tissue tract over time. A particular advantage of this method for creating the access tract is that the tract will be formed simultaneously with healing of the surgical introduction of the port and associated subcutaneous cannula. A further advantage, when an access tube is used as the penetrating element, is that fluids may be introduced and removed from the port during the healing period. - Once implanted, the
port 10 will have an aperture oropening 25 which is preferably oriented to receive a vertically aligned needle. That is, the access needle N will preferably be percutaneously introduced through the skin surface in a direction which is normal to or perpendicular to the plane of the skin at the point where the needle is being introduced. While vertical access is preferred and may be accomplished using the exemplary ports of the present invention, percutaneous access according to the present invention may also be achieved used non-vertical access direction, i.e. where access is accomplished by penetrating a needle or other device at a relatively low angle relative to the skin, often between 15° and 45° relative to the skin surface. Preferably, theport 10 of the present invention does not have a needle guide channel, trough, or extended funnel at the opening ofpassage 20 since such a funnel or trough may allow the user to penetrate the access tube through different access tracts. - After entering the
port 10, the access needle N will preferably engage with a tapered portion of theupstream end 22 ofpassage 20 to form a seal. The needle N does not engage thevalve element 40, which in the preferred embodiment, is located in a portion of thepassage 20 oriented at a 90° to theupstream end 22. The access tube may inserted using a method as further described in commonly assigned, copending application Ser. No. 09/238,461 (Attorney Docket No. 17742-000620 entitled Devices and Methods for Accessing an Implanted Port, filed Jan. 29, 1999), the full disclosure of which is incorporated herein by reference. The access tube or needle N is inserted to establish a flow path with a lumen incannula 30, where the cannula may be connected to a blood vessel or other body lumen or cavity, as described in detail in co-pending application Ser. No. 08/856,641, filed on May 15, 1997, now U.S. Pat. No. 5,931,829. The access needle N may be aligned over theaperture 25 by manually feeling the top of theport 10. Theport 10 is generally symmetric with theaperture 25 positioned in the center of the port. The user can feel the periphery of the port P and visually determine its center. The access needle N is then vertically penetrated through the skin and into the aperture, as shown inFIG. 8 . The thickness of tissue T overlying the aperture is generally from 3 mm to 15 mm, as described above. - Withdrawal of the needle will leave a tissue tract TT through the tissue T overlying the port 10 (as shown in
FIG. 9 ). Because theinternal valve element 40 ofport 10 will have closed, fluid from the body lumen such as the peritoneum, a blood vessel, tissue catheter, or other cavities will be inhibited. Both the vertical orientation of needle entry and the valve which inhibits back bleeding or fluid backflow into the tissue tract after withdrawal of the needle, contribute to the lessening or elimination of scab formation and reduction in patient trauma and rapid healing in a non-fibrous manner. Surprisingly, such benefits may be achieved even when using the preferred large bore access needles described above. The rapid healing and minimum trauma have been found even when the port is accessed as many as four times per day or more. Additionally, ports may be irrigated with anti-microbial cleaning fluids when a needle smaller than the needle seal diameter is used. - Referring now to
FIG. 10 , aport 10 may be packaged together with instructions for use (IFU) in a kit. Aconventional package 100, which may be in the form of a pouch, tray, box, tube, or the like, may be used to contain both the port and the instructions for use. Additional kit components, such as a penetrating element, access tube, a catheter, or the like, may also be included in the kit. Optionally, but not necessarily, all kit components may be sterilized within the package, and the instructions for use may be set forth on a separate sheet of paper and/or on the packaging itself. The instructions may set forth any of the aspects of the method of the present invention for implanting the port or subsequently accessing the port using an access tube as described above. - While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
Claims (16)
1. An implantable port comprising:
a body having a flow passage therethrough, said flow passage having an upstream end and a downstream end, wherein at least a portion of the upstream end is adapted to sealingly engage an access tube which is inserted into said upstream end;
a pressure-responsive valve element positioned in the flow passage and integrally formed with the port body downstream from the upstream portion so that an access tube can be fully inserted into said upstream portion without engaging the valve component, wherein the valve component is closed in the absence of a differential pressure above a threshold level; and
a cannula connected at a proximal end of the flow passage and having a distal end adapted to connect to a blood vessel.
2. An implantable port as in claim 1 , wherein said port body comprises a housing and a housing insert coupled to said housing.
3. An implantable port as in claim 2 , wherein the pressure-responsive valve element is integrally formed in the housing insert.
4. An implantable port as in claim 2 wherein said insert comprises a compliant material defining a portion of the flow passage.
5. An implantable port as in claim 2 wherein said portion of the upstream end of the housing adapted to sealingly engage the access tube has a radial stiffness greater than a radial stiffness of said access tube.
6. An implantable port as in claim 2 wherein said housing comprises stainless steel.
7. An implantable port as in claim 2 wherein the housing defines a first portion of the passage and the insert defines a second portion of the passage.
8. An implantable port as in claim 7 wherein the first portion of the passage has a distal opening with a diameter smaller than a diameter of the access tube.
9. An implantable port as in claim 1 , wherein the downstream end of the flow passage is disclosed at about a 90° angle relative to the upstream end which receives the access tube.
10. An implantable port as in claim 1 wherein the passage does not have a needle guide channel coupled to the body and upstream of the upstream end of the passage.
11. An implantable port as in claim 1 , wherein said valve element comprises a pressure-responsive slit valve.
12. An implantable port as in claim 1 , wherein said valve element comprises an articulating, pressure-responsive leaflet valve.
13. An implantable port as in claim 1 , wherein the threshold valve of the differential pressure is between about 0.25 and 25.0 psi.
14. A kit comprising:
a subcutaneously implantable port according to claim 1;
instructions for implanting the port comprising implanting a port in a subcutaneous tissue pocket, wherein an access cannula-receiving aperture of the port is disposed beneath an intact region of skin, and introducing a penetrating element through the intact region of skin into the aperture, wherein the element remains anchored in the aperture for a time sufficient to create an access tract; and
a package adapted to contain the port and the instructions for use.
15. A kit as in claim 14 , further comprising a penetrating element.
16. A kit as in claim 15 , wherein the penetrating element comprises a syringe needle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/130,932 US20050209573A1 (en) | 1994-01-18 | 2005-05-16 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/183,151 US5562617A (en) | 1994-01-18 | 1994-01-18 | Implantable vascular device |
US48011795A | 1995-06-07 | 1995-06-07 | |
US08/634,634 US5713859A (en) | 1994-01-18 | 1996-04-18 | Implantable vascular device |
US08/745,903 US5755780A (en) | 1994-01-18 | 1996-11-07 | Implantable vascular device |
US09/017,045 US6056717A (en) | 1994-01-18 | 1998-02-02 | Implantable vascular device |
US23941199A | 1999-01-28 | 1999-01-28 | |
US56137400A | 2000-04-28 | 2000-04-28 | |
US09/595,167 US6929631B1 (en) | 1994-01-18 | 2000-06-15 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
US11/130,932 US20050209573A1 (en) | 1994-01-18 | 2005-05-16 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/634,634 Continuation US5713859A (en) | 1994-01-18 | 1996-04-18 | Implantable vascular device |
US09/595,167 Continuation US6929631B1 (en) | 1994-01-18 | 2000-06-15 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050209573A1 true US20050209573A1 (en) | 2005-09-22 |
Family
ID=34831545
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/595,167 Expired - Fee Related US6929631B1 (en) | 1994-01-18 | 2000-06-15 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
US11/130,932 Abandoned US20050209573A1 (en) | 1994-01-18 | 2005-05-16 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/595,167 Expired - Fee Related US6929631B1 (en) | 1994-01-18 | 2000-06-15 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Country Status (1)
Country | Link |
---|---|
US (2) | US6929631B1 (en) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2907017A1 (en) * | 2006-10-16 | 2008-04-18 | Cie Euro Etude Rech Paroscopie | Implantable medical device e.g. implantable pump, for e.g. controlled diffusion of drug into vessel of human patient, has stabilizing unit partly separated from main body and remaining in body of human/animal patient |
US20090209918A1 (en) * | 2007-09-07 | 2009-08-20 | Imtec, Llc | Method and device for dialysis |
US20100152640A1 (en) * | 2008-09-05 | 2010-06-17 | Imtecbiomedical, Inc. | Methods and apparatus for vascular access |
US7785302B2 (en) | 2005-03-04 | 2010-08-31 | C. R. Bard, Inc. | Access port identification systems and methods |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US8021324B2 (en) | 2007-07-19 | 2011-09-20 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US8025639B2 (en) | 2005-04-27 | 2011-09-27 | C. R. Bard, Inc. | Methods of power injecting a fluid through an access port |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US20110270187A1 (en) * | 2010-04-28 | 2011-11-03 | Nelson Brian D | Body portal anchors and systems |
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
US8202259B2 (en) | 2005-03-04 | 2012-06-19 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8257325B2 (en) | 2007-06-20 | 2012-09-04 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
US8398654B2 (en) | 2008-04-17 | 2013-03-19 | Allergan, Inc. | Implantable access port device and attachment system |
US8409221B2 (en) | 2008-04-17 | 2013-04-02 | Allergan, Inc. | Implantable access port device having a safety cap |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
US8506532B2 (en) | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
US8641676B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
US8715158B2 (en) | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
US8715244B2 (en) | 2009-07-07 | 2014-05-06 | C. R. Bard, Inc. | Extensible internal bolster for a medical device |
US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
US8882728B2 (en) | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
US8882655B2 (en) | 2010-09-14 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable access port system |
US8905916B2 (en) | 2010-08-16 | 2014-12-09 | Apollo Endosurgery, Inc. | Implantable access port system |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
US9079004B2 (en) | 2009-11-17 | 2015-07-14 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
US9125718B2 (en) | 2010-04-30 | 2015-09-08 | Apollo Endosurgery, Inc. | Electronically enhanced access port for a fluid filled implant |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US9295773B2 (en) | 2010-11-09 | 2016-03-29 | Frank Prosl | Hemodialysis access system |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
EP3307374A4 (en) * | 2015-06-11 | 2019-04-10 | Proviflo, LLC | Graft-port hemodialysis systems, devices and methods |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
US10463845B2 (en) | 2013-01-23 | 2019-11-05 | C.R. Bard, Inc. | Low-profile access port |
USD870264S1 (en) | 2017-09-06 | 2019-12-17 | C. R. Bard, Inc. | Implantable apheresis port |
US11420033B2 (en) | 2013-01-23 | 2022-08-23 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
US11464960B2 (en) | 2013-01-23 | 2022-10-11 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
WO2022251616A1 (en) * | 2021-05-28 | 2022-12-01 | Icahn School Of Medicine At Mount Sinai | Vascular access devices with self-sealing valves |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US7101356B2 (en) * | 2001-03-23 | 2006-09-05 | Miller Stuart H | Implantable vascular access device |
EP1395185B1 (en) | 2001-06-12 | 2010-10-27 | Pelikan Technologies Inc. | Electric lancet actuator |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7344507B2 (en) | 2002-04-19 | 2008-03-18 | Pelikan Technologies, Inc. | Method and apparatus for lancet actuation |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
CA2448902C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
WO2002100254A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7198606B2 (en) | 2002-04-19 | 2007-04-03 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with analyte sensing |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
ES2490740T3 (en) | 2003-06-06 | 2014-09-04 | Sanofi-Aventis Deutschland Gmbh | Apparatus for blood fluid sampling and analyte detection |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7435236B2 (en) | 2003-06-27 | 2008-10-14 | Navilyst Medical, Inc. | Pressure actuated valve with improved biasing member |
EP1671096A4 (en) | 2003-09-29 | 2009-09-16 | Pelikan Technologies Inc | Method and apparatus for an improved sample capture device |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
US20050131383A1 (en) * | 2003-12-16 | 2005-06-16 | How-Lun Chen | Method for implanting flexible injection port |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
WO2005065414A2 (en) | 2003-12-31 | 2005-07-21 | Pelikan Technologies, Inc. | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
CN100435881C (en) * | 2007-04-05 | 2008-11-26 | 武汉理工大学 | Transdermal element with airbag type switch |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
US8257321B2 (en) | 2008-05-21 | 2012-09-04 | Navilyst Medical, Inc. | Pressure activated valve for high flow rate and pressure venous access applications |
WO2010048527A2 (en) * | 2008-10-23 | 2010-04-29 | Marwan Tabbara | Surgical mehods, devices, and kits |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8007468B2 (en) | 2009-07-13 | 2011-08-30 | Navilyst Medical, Inc. | Method to secure an elastic component in a valve |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9707339B2 (en) | 2012-03-28 | 2017-07-18 | Angiodynamics, Inc. | High flow rate dual reservoir port system |
US9713704B2 (en) | 2012-03-29 | 2017-07-25 | Bradley D. Chartrand | Port reservoir cleaning system and method |
US9895524B2 (en) | 2012-07-13 | 2018-02-20 | Angiodynamics, Inc. | Fluid bypass device for valved catheters |
US9205242B2 (en) * | 2012-11-19 | 2015-12-08 | Angiodynamics, Inc. | Port septum with integral valve |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
US10716891B2 (en) * | 2015-04-07 | 2020-07-21 | Isaab Innovations Llc | Implantable fluid delivery system |
US10610678B2 (en) | 2016-08-11 | 2020-04-07 | Angiodynamics, Inc. | Bi-directional, pressure-actuated medical valve with improved fluid flow control and method of using such |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181132A (en) * | 1977-05-31 | 1980-01-01 | Parks Leon C | Method and apparatus for effecting hyperthermic treatment |
US4464178A (en) * | 1981-11-25 | 1984-08-07 | Dalton Michael J | Method and apparatus for administration of fluids |
US4534759A (en) * | 1981-07-16 | 1985-08-13 | Trawoeger Werner | Valve for supplying, controlling and taking out a medium contained in an implanted container |
US4544371A (en) * | 1982-10-05 | 1985-10-01 | American Hospital Supply Corporation | Implantable metered dose drug delivery system |
US4569675A (en) * | 1983-09-12 | 1986-02-11 | Infusaid Corporation | Transcutaneous infusion system |
US4639247A (en) * | 1984-11-02 | 1987-01-27 | Carbomedics, Inc. | Percutaneous access device |
US4681560A (en) * | 1984-03-16 | 1987-07-21 | Pudenz-Schulte Medical Research Corp. | Subcutaneous infusion reservoir and pump system |
US4705501A (en) * | 1982-04-12 | 1987-11-10 | Regents Of The University Of Minnesota | Bi-directional, anti-reflux vascular access system |
US4846806A (en) * | 1987-10-06 | 1989-07-11 | 501 Regents Of University Of Minnesota | Implantable intravascular access system |
US4850955A (en) * | 1986-12-02 | 1989-07-25 | Codman & Shurtleff | Body fluid transfer device |
US4892518A (en) * | 1987-12-04 | 1990-01-09 | Biocontrol Technology, Inc. | Hemodialysis |
US5053013A (en) * | 1990-03-01 | 1991-10-01 | The Regents Of The University Of Michigan | Implantable infusion device |
US5057084A (en) * | 1990-03-01 | 1991-10-15 | The Regents Of The University Of Michigan | Implantable infusion device |
US5098405A (en) * | 1991-01-31 | 1992-03-24 | Becton, Dickinson And Company | Apparatus and method for a side port cathether adapter with a one piece integral combination valve |
US5125897A (en) * | 1990-04-27 | 1992-06-30 | Corpak, Inc. | Gastrostomy device with one-way valve and cuff pin |
US5147318A (en) * | 1991-03-04 | 1992-09-15 | Board Of Regents, The University Of Texas System | Valved arterial catheter |
US5180365A (en) * | 1990-03-01 | 1993-01-19 | Ensminger William D | Implantable infusion device |
US5190525A (en) * | 1990-12-21 | 1993-03-02 | Abbott Laboratories | Drug infusion manifold |
US5226879A (en) * | 1990-03-01 | 1993-07-13 | William D. Ensminger | Implantable access device |
US5257971A (en) * | 1993-03-16 | 1993-11-02 | Minimed Technologies, Ltd. | Recondition process for a medication infusion pump |
US5263930A (en) * | 1990-03-01 | 1993-11-23 | William D. Ensminger | Implantable access devices |
US5281199A (en) * | 1990-03-01 | 1994-01-25 | Michigan Transtech Corporation | Implantable access devices |
US5290263A (en) * | 1989-02-02 | 1994-03-01 | Regents Of The University Of Minnesota | Bidirectional check valve catheter |
US5350360A (en) * | 1990-03-01 | 1994-09-27 | Michigan Transtech Corporation | Implantable access devices |
US5520643A (en) * | 1990-03-01 | 1996-05-28 | Michigan Transtech Corporation | Implantable access devices |
US5562617A (en) * | 1994-01-18 | 1996-10-08 | Finch, Jr.; Charles D. | Implantable vascular device |
US5702363A (en) * | 1995-06-07 | 1997-12-30 | Flaherty; J. Christopher | Septumless implantable treatment material device |
US5741228A (en) * | 1995-02-17 | 1998-04-21 | Strato/Infusaid | Implantable access device |
US5897528A (en) * | 1998-04-30 | 1999-04-27 | Medtronic, Inc. | Filtered intracerebroventricular or intraspinal access port with direct cerebrospinal fluid access |
US5989239A (en) * | 1997-01-21 | 1999-11-23 | Vasca, Inc. | Method and apparatus for percutaneously accessing an implanted port |
US6162238A (en) * | 1999-02-24 | 2000-12-19 | Aaron V. Kaplan | Apparatus and methods for control of body lumens |
US6206871B1 (en) * | 1996-07-08 | 2001-03-27 | Claudio Zanon | Surgical kit for implantation of an injection site |
US6299609B1 (en) * | 1998-01-07 | 2001-10-09 | Vasca, Inc. | Methods and apparatus for inhibiting infection of subcutaneously implanted devices |
US6478783B1 (en) * | 2000-05-26 | 2002-11-12 | H. Robert Moorehead | Anti-sludge medication ports and related methods |
US6544214B1 (en) * | 1999-05-25 | 2003-04-08 | Dsu Medical Corporation | Subcutaneous access needle and method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000129A1 (en) | 1991-06-20 | 1993-01-07 | Milosevic Zeljko | Implantable port |
DE4129782C1 (en) | 1991-09-07 | 1992-10-08 | Hans Dipl.-Ing. Dr.Med. 3015 Wennigsen De Haindl | |
US5575770A (en) | 1995-04-05 | 1996-11-19 | Therex Corporation | Implantable drug infusion system with safe bolus capability |
US6013058A (en) | 1996-06-12 | 2000-01-11 | Biolink Corporation | Device for subcutaneous accessibility |
-
2000
- 2000-06-15 US US09/595,167 patent/US6929631B1/en not_active Expired - Fee Related
-
2005
- 2005-05-16 US US11/130,932 patent/US20050209573A1/en not_active Abandoned
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181132A (en) * | 1977-05-31 | 1980-01-01 | Parks Leon C | Method and apparatus for effecting hyperthermic treatment |
US4534759A (en) * | 1981-07-16 | 1985-08-13 | Trawoeger Werner | Valve for supplying, controlling and taking out a medium contained in an implanted container |
US4464178A (en) * | 1981-11-25 | 1984-08-07 | Dalton Michael J | Method and apparatus for administration of fluids |
US4705501A (en) * | 1982-04-12 | 1987-11-10 | Regents Of The University Of Minnesota | Bi-directional, anti-reflux vascular access system |
US4544371A (en) * | 1982-10-05 | 1985-10-01 | American Hospital Supply Corporation | Implantable metered dose drug delivery system |
US4569675A (en) * | 1983-09-12 | 1986-02-11 | Infusaid Corporation | Transcutaneous infusion system |
US4681560A (en) * | 1984-03-16 | 1987-07-21 | Pudenz-Schulte Medical Research Corp. | Subcutaneous infusion reservoir and pump system |
US4639247A (en) * | 1984-11-02 | 1987-01-27 | Carbomedics, Inc. | Percutaneous access device |
US4850955A (en) * | 1986-12-02 | 1989-07-25 | Codman & Shurtleff | Body fluid transfer device |
US4846806A (en) * | 1987-10-06 | 1989-07-11 | 501 Regents Of University Of Minnesota | Implantable intravascular access system |
US4892518A (en) * | 1987-12-04 | 1990-01-09 | Biocontrol Technology, Inc. | Hemodialysis |
US5290263A (en) * | 1989-02-02 | 1994-03-01 | Regents Of The University Of Minnesota | Bidirectional check valve catheter |
US5263930A (en) * | 1990-03-01 | 1993-11-23 | William D. Ensminger | Implantable access devices |
US5520643A (en) * | 1990-03-01 | 1996-05-28 | Michigan Transtech Corporation | Implantable access devices |
US5527277A (en) * | 1990-03-01 | 1996-06-18 | Michigan Transtech Corporation | Implantable access devices |
US5527278A (en) * | 1990-03-01 | 1996-06-18 | Michigan Transtech Corporation | Implantable access devices |
US5180365A (en) * | 1990-03-01 | 1993-01-19 | Ensminger William D | Implantable infusion device |
US5503630A (en) * | 1990-03-01 | 1996-04-02 | Michigan Transtech Corporation | Inplantable access devices |
US5226879A (en) * | 1990-03-01 | 1993-07-13 | William D. Ensminger | Implantable access device |
US5476451A (en) * | 1990-03-01 | 1995-12-19 | Michigan Transtech Corporation | Implantable access devices |
US5057084A (en) * | 1990-03-01 | 1991-10-15 | The Regents Of The University Of Michigan | Implantable infusion device |
US5281199A (en) * | 1990-03-01 | 1994-01-25 | Michigan Transtech Corporation | Implantable access devices |
US5053013A (en) * | 1990-03-01 | 1991-10-01 | The Regents Of The University Of Michigan | Implantable infusion device |
US5350360A (en) * | 1990-03-01 | 1994-09-27 | Michigan Transtech Corporation | Implantable access devices |
US5417656A (en) * | 1990-03-01 | 1995-05-23 | Michigan Transtech Corporation | Implantable access devices |
US5125897A (en) * | 1990-04-27 | 1992-06-30 | Corpak, Inc. | Gastrostomy device with one-way valve and cuff pin |
US5190525A (en) * | 1990-12-21 | 1993-03-02 | Abbott Laboratories | Drug infusion manifold |
US5098405A (en) * | 1991-01-31 | 1992-03-24 | Becton, Dickinson And Company | Apparatus and method for a side port cathether adapter with a one piece integral combination valve |
US5147318A (en) * | 1991-03-04 | 1992-09-15 | Board Of Regents, The University Of Texas System | Valved arterial catheter |
US5257971A (en) * | 1993-03-16 | 1993-11-02 | Minimed Technologies, Ltd. | Recondition process for a medication infusion pump |
US5713859A (en) * | 1994-01-18 | 1998-02-03 | Vasca, Inc. | Implantable vascular device |
US5562617A (en) * | 1994-01-18 | 1996-10-08 | Finch, Jr.; Charles D. | Implantable vascular device |
US5741228A (en) * | 1995-02-17 | 1998-04-21 | Strato/Infusaid | Implantable access device |
US5702363A (en) * | 1995-06-07 | 1997-12-30 | Flaherty; J. Christopher | Septumless implantable treatment material device |
US6206871B1 (en) * | 1996-07-08 | 2001-03-27 | Claudio Zanon | Surgical kit for implantation of an injection site |
US5989239A (en) * | 1997-01-21 | 1999-11-23 | Vasca, Inc. | Method and apparatus for percutaneously accessing an implanted port |
US6299609B1 (en) * | 1998-01-07 | 2001-10-09 | Vasca, Inc. | Methods and apparatus for inhibiting infection of subcutaneously implanted devices |
US5897528A (en) * | 1998-04-30 | 1999-04-27 | Medtronic, Inc. | Filtered intracerebroventricular or intraspinal access port with direct cerebrospinal fluid access |
US6162238A (en) * | 1999-02-24 | 2000-12-19 | Aaron V. Kaplan | Apparatus and methods for control of body lumens |
US6544214B1 (en) * | 1999-05-25 | 2003-04-08 | Dsu Medical Corporation | Subcutaneous access needle and method |
US6478783B1 (en) * | 2000-05-26 | 2002-11-12 | H. Robert Moorehead | Anti-sludge medication ports and related methods |
Cited By (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
US8608713B2 (en) | 1998-12-07 | 2013-12-17 | C. R. Bard, Inc. | Septum feature for identification of an access port |
US10238850B2 (en) | 2005-03-04 | 2019-03-26 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US8382724B2 (en) | 2005-03-04 | 2013-02-26 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US7959615B2 (en) | 2005-03-04 | 2011-06-14 | C. R. Bard, Inc. | Access port identification systems and methods |
US10857340B2 (en) | 2005-03-04 | 2020-12-08 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US10675401B2 (en) | 2005-03-04 | 2020-06-09 | Bard Peripheral Vascular, Inc. | Access port identification systems and methods |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US10265512B2 (en) | 2005-03-04 | 2019-04-23 | Bard Peripheral Vascular, Inc. | Implantable access port including a sandwiched radiopaque insert |
US10179230B2 (en) | 2005-03-04 | 2019-01-15 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US8202259B2 (en) | 2005-03-04 | 2012-06-19 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8603052B2 (en) | 2005-03-04 | 2013-12-10 | C. R. Bard, Inc. | Access port identification systems and methods |
US7785302B2 (en) | 2005-03-04 | 2010-08-31 | C. R. Bard, Inc. | Access port identification systems and methods |
US10905868B2 (en) | 2005-03-04 | 2021-02-02 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US8382723B2 (en) | 2005-03-04 | 2013-02-26 | C. R. Bard, Inc. | Access port identification systems and methods |
US9682186B2 (en) | 2005-03-04 | 2017-06-20 | C. R. Bard, Inc. | Access port identification systems and methods |
US9603992B2 (en) | 2005-03-04 | 2017-03-28 | C. R. Bard, Inc. | Access port identification systems and methods |
US9603993B2 (en) | 2005-03-04 | 2017-03-28 | C. R. Bard, Inc. | Access port identification systems and methods |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
US8998860B2 (en) | 2005-03-04 | 2015-04-07 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8939947B2 (en) | 2005-03-04 | 2015-01-27 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US8585663B2 (en) | 2005-03-04 | 2013-11-19 | C. R. Bard, Inc. | Access port identification systems and methods |
US11077291B2 (en) | 2005-03-04 | 2021-08-03 | Bard Peripheral Vascular, Inc. | Implantable access port including a sandwiched radiopaque insert |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
US10780257B2 (en) | 2005-04-27 | 2020-09-22 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8641688B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US10052470B2 (en) | 2005-04-27 | 2018-08-21 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US9937337B2 (en) | 2005-04-27 | 2018-04-10 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US10183157B2 (en) | 2005-04-27 | 2019-01-22 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US10625065B2 (en) | 2005-04-27 | 2020-04-21 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8475417B2 (en) | 2005-04-27 | 2013-07-02 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US8805478B2 (en) | 2005-04-27 | 2014-08-12 | C. R. Bard, Inc. | Methods of performing a power injection procedure including identifying features of a subcutaneously implanted access port for delivery of contrast media |
US8545460B2 (en) | 2005-04-27 | 2013-10-01 | C. R. Bard, Inc. | Infusion apparatuses and related methods |
US10661068B2 (en) | 2005-04-27 | 2020-05-26 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US9421352B2 (en) | 2005-04-27 | 2016-08-23 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US8641676B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US10016585B2 (en) | 2005-04-27 | 2018-07-10 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8025639B2 (en) | 2005-04-27 | 2011-09-27 | C. R. Bard, Inc. | Methods of power injecting a fluid through an access port |
FR2907017A1 (en) * | 2006-10-16 | 2008-04-18 | Cie Euro Etude Rech Paroscopie | Implantable medical device e.g. implantable pump, for e.g. controlled diffusion of drug into vessel of human patient, has stabilizing unit partly separated from main body and remaining in body of human/animal patient |
US11878137B2 (en) | 2006-10-18 | 2024-01-23 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US10556090B2 (en) | 2006-11-08 | 2020-02-11 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US10092725B2 (en) | 2006-11-08 | 2018-10-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US8852160B2 (en) | 2007-06-20 | 2014-10-07 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US11406808B2 (en) | 2007-06-20 | 2022-08-09 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US8257325B2 (en) | 2007-06-20 | 2012-09-04 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US11478622B2 (en) | 2007-06-20 | 2022-10-25 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US9533133B2 (en) | 2007-06-20 | 2017-01-03 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US10874842B2 (en) | 2007-07-19 | 2020-12-29 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US10639465B2 (en) | 2007-07-19 | 2020-05-05 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US8021324B2 (en) | 2007-07-19 | 2011-09-20 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US9517329B2 (en) | 2007-07-19 | 2016-12-13 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US20090209918A1 (en) * | 2007-09-07 | 2009-08-20 | Imtec, Llc | Method and device for dialysis |
US10086186B2 (en) | 2007-11-07 | 2018-10-02 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US10792485B2 (en) | 2007-11-07 | 2020-10-06 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US11638810B2 (en) | 2007-11-07 | 2023-05-02 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US8398654B2 (en) | 2008-04-17 | 2013-03-19 | Allergan, Inc. | Implantable access port device and attachment system |
US9023062B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device and attachment system |
US8409221B2 (en) | 2008-04-17 | 2013-04-02 | Allergan, Inc. | Implantable access port device having a safety cap |
US9023063B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device having a safety cap |
US20100152640A1 (en) * | 2008-09-05 | 2010-06-17 | Imtecbiomedical, Inc. | Methods and apparatus for vascular access |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US10052471B2 (en) | 2008-11-13 | 2018-08-21 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US10773066B2 (en) | 2008-11-13 | 2020-09-15 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8715244B2 (en) | 2009-07-07 | 2014-05-06 | C. R. Bard, Inc. | Extensible internal bolster for a medical device |
US8506532B2 (en) | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
US8715158B2 (en) | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
US10912935B2 (en) | 2009-11-17 | 2021-02-09 | Bard Peripheral Vascular, Inc. | Method for manufacturing a power-injectable access port |
US9079004B2 (en) | 2009-11-17 | 2015-07-14 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US9248268B2 (en) | 2009-11-17 | 2016-02-02 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US9717895B2 (en) | 2009-11-17 | 2017-08-01 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US11759615B2 (en) | 2009-11-17 | 2023-09-19 | Bard Peripheral Vascular, Inc. | Overmolded access port including anchoring and identification features |
US10155101B2 (en) | 2009-11-17 | 2018-12-18 | Bard Peripheral Vascular, Inc. | Overmolded access port including anchoring and identification features |
US8882728B2 (en) | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
US9427553B2 (en) | 2010-04-28 | 2016-08-30 | Medtronic, Inc. | Body portal anchors and systems |
US20110270187A1 (en) * | 2010-04-28 | 2011-11-03 | Nelson Brian D | Body portal anchors and systems |
US8738151B2 (en) * | 2010-04-28 | 2014-05-27 | Medtronic, Inc. | Body portal anchors and systems |
US9125718B2 (en) | 2010-04-30 | 2015-09-08 | Apollo Endosurgery, Inc. | Electronically enhanced access port for a fluid filled implant |
US9241819B2 (en) | 2010-04-30 | 2016-01-26 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
US8905916B2 (en) | 2010-08-16 | 2014-12-09 | Apollo Endosurgery, Inc. | Implantable access port system |
US8882655B2 (en) | 2010-09-14 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable access port system |
US9295773B2 (en) | 2010-11-09 | 2016-03-29 | Frank Prosl | Hemodialysis access system |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
US11420033B2 (en) | 2013-01-23 | 2022-08-23 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
US11464960B2 (en) | 2013-01-23 | 2022-10-11 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
US10463845B2 (en) | 2013-01-23 | 2019-11-05 | C.R. Bard, Inc. | Low-profile access port |
US10456570B2 (en) | 2015-06-11 | 2019-10-29 | Proviflo, Llc | Graft-port hemodialysis systems, devices, and methods |
US20200038645A1 (en) * | 2015-06-11 | 2020-02-06 | Proviflo, Llc | Graft-port hemodialysis systems, devices, and methods |
US11690991B2 (en) * | 2015-06-11 | 2023-07-04 | Proviflo, Llc | Graft-port hemodialysis systems, devices, and methods |
EP3307374A4 (en) * | 2015-06-11 | 2019-04-10 | Proviflo, LLC | Graft-port hemodialysis systems, devices and methods |
USD885557S1 (en) | 2017-09-06 | 2020-05-26 | C. R. Bard, Inc. | Implantable apheresis port |
USD870264S1 (en) | 2017-09-06 | 2019-12-17 | C. R. Bard, Inc. | Implantable apheresis port |
WO2022251616A1 (en) * | 2021-05-28 | 2022-12-01 | Icahn School Of Medicine At Mount Sinai | Vascular access devices with self-sealing valves |
Also Published As
Publication number | Publication date |
---|---|
US6929631B1 (en) | 2005-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6929631B1 (en) | Method and apparatus for percutaneously accessing a pressure activated implanted port | |
US5989239A (en) | Method and apparatus for percutaneously accessing an implanted port | |
US6120492A (en) | Method and apparatus for percutaneously accessing an implanted port | |
US6007516A (en) | Valve port and method for vascular access | |
EP1016431B1 (en) | Implantable access devices | |
US7056316B1 (en) | Valve port and method for vascular access | |
US5356381A (en) | Implantable access devices | |
US6962577B2 (en) | Implantable hemodialysis access device | |
US5057084A (en) | Implantable infusion device | |
EP0809523B1 (en) | Implantable access device | |
US4464178A (en) | Method and apparatus for administration of fluids | |
US7927325B2 (en) | Implantable pump connector for catheter attachment | |
US11690991B2 (en) | Graft-port hemodialysis systems, devices, and methods | |
WO2004075970A1 (en) | Chemical injecion port | |
WO2000044419A9 (en) | Method and apparatus for percutaneously accessing a pressure activated implanted port | |
JPH08107934A (en) | Cap for subcutaneous embedment type medicinal liquid injecting port sleeve | |
JP3137360B2 (en) | Chemical injection port | |
EP1229902A1 (en) | Valve port and method for vascular access | |
JP3169547B2 (en) | Chemical injection port | |
CA1234029A (en) | Peritoneal injection catheter apparatus and methods | |
IE912287A1 (en) | Implantable infusion device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |